The Federal Government has announced that Nigeria will receive consignments of Lenacapavir, a groundbreaking drug for HIV prevention, in March 2026.
According to the National Agency for the Control of AIDS (NACA), preparations are already in advanced stages for the introduction and nationwide rollout of the drug as part of Nigeria’s Pre Exposure Prophylaxis (PrEP) programme.
Lenacapavir represents a major shift in HIV prevention because it is a long acting injectable drug taken only twice a year, unlike traditional PrEP medicines that require daily pills.
Clinical trials have shown that the injection significantly reduces the risk of HIV infection and can provide near total protection when used correctly.
NACA said the move is part of Nigeria’s strategy to accelerate progress towards controlling the HIV epidemic and strengthening prevention programmes across the country.
The agency confirmed that the drug has already received regulatory approval from the National Agency for Food and Drug Administration and Control (NAFDAC), clearing the way for its importation and deployment.
To prepare for the rollout, readiness assessments have already been conducted in 10 states to evaluate health facilities and identify implementation needs.
The states include:
Akwa Ibom
Anambra
Benue
Cross River
Ebonyi
FCT
Gombe
Kano
Kwara
Lagos
NACA also disclosed that it has completed a national training of trainers in Abuja, followed by step down training for healthcare workers in the selected states. The goal is to ensure that health professionals are fully prepared to administer the injection safely and provide proper counselling to patients.
In addition, the agency has developed information, education and communication materials to create awareness and encourage uptake of the new HIV prevention option once supplies arrive.
Health experts believe the introduction of Lenacapavir could significantly strengthen HIV prevention efforts in Nigeria, especially among high risk populations.
If properly implemented, the twice yearly injection could help overcome one of the biggest challenges of HIV prevention which is poor adherence to daily PrEP medication.
